Abstract
The bile acid receptor FXR has emerged as a bona fide drug target for chronic cholestatic and metabolic liver diseases, ahead of all non-alcoholic fat......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
